Shimon Eckhouse, PhD
Chairman at Syneron
Dr. Shimon Eckhouse Chairman of the Board of Directors Director Since: 2004 Dr. Shimon Eckhouse is a co-founder of Syneron and a co-developer of the proprietary elos technology on which Syneron's aesthetic medical devices are based. Dr. Eckhouse was also the inventor and developer of IPL technology, another fundamental cornerstone of non-invasive aesthetic medical devices.
In addition to serving as active chairman at Syneron, Dr. Eckhouse is also the chairman and co-founder of CardioDex Ltd., NanoCyte Ltd., Navotek Ltd., Tulip Ltd., Rapid Medical Ltd., Opticul Diagnostic Ltd., RealView Ltd. and the Chairman of Orsense Ltd. Dr. Eckhouse was a co-founder of ColorChip and has served as its chairman and CEO from 2001 to 2003. He was a co-founder of Ventor Medical Technologies Ltd. and served as its Chairman until it was acquired by Medtronic in February 2009. Dr. Eckhouse was the chairman and CEO of ESC Medical Systems from its inception in 1992 until 1999. He also previously worked at Rafael, Armament Development Authority of Israel as a scientist, team leader and head of department and was active in various areas of R&D including lasers and electro-optics.
Dr. Eckhouse holds a B.Sc. in physics from the Technion Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He has more than 20 registered patents and published more than 50 papers in leading reference journals and conferences. He is also a member of the Board of Directors of the Technion Israeli Institute of Technology.
Michael Greenberg, MD
Partner, Treasurer at Illinois Dermatology Institute
Dr. Michael A. Greenberg specializes in medical and cosmetic dermatology at the Elk Grove office of the Illinois Dermatology Institute, with a focus on treating patients with an emotional or spiritual component to their skin condition. As a co-founder of IDI, Dr. Greenberg embraces the benefits of a group practice, stating that "practicing in a group that is more family than corporate has added to my joy of being a physician."
Dr. Greenberg graduated with his undergraduate degree in Biology from Case Western Reserve University, and then received his medical degree from the University of Illinois in Chicago. His postgraduate training included a residency at the University of Illinois Hospital, where he served as Chief Resident during his final year.
Dr. Greenberg has hosted a bi-weekly radio show for medical professionals on XM160, written a column for American Medical News, and published two books. He guest lectures to students at the University of Paris Decartes Medical School on issues of communication and humanism. Throughout his career, Dr. Greenberg has had articles published discussing his goal of increasing the care and compassion providing by medical professionals today.
CEO, Nocicept Technologies, Inc.
Philippe Burnham has spent 30+ years in blue chip pharma, including Pharmacia and Upjohn, Roche and Valeant. Launches include Rogaine, Xenical, Neotensil; on Valeant acquisition teams for Medicis and Obagi.
Nocicept Technologies is focused on rapid commercialization of market disruptive, game-changing topical anesthetics that offer 2+ hours of injection-like numbing at unprecedented depths, in as a little as 5 minutes. The company is part of an incubator-accelerator holding company based in Thousand Oaks, CA that creates and acquires innovative technology applications to address today’s unmet market needs.
Robert E. Grant
CEO & Founder at ALPHAEON Corporation a Strathspey Crown company
Mr. Grant brings his tremendous experience in innovation and dynamic growth for Fortune 500 companies to his role as CEO of ALPHAEON. For over 20 years, he has played a pivotal role in successful technology and business development in pharmaceutical, medical device, and healthcare markets.
Most recently, he was CEO and President of Bausch+Lomb Surgical, leading the significant growth of their product portfolio. In 2006-2010, Mr. Grant was President of Allergan Medical, leading the $3.2 billion Inamed acquisition and the commercial success of Botox Cosmetic, Juvederm, Natrelle breast implants, and Lap-Band brands. Beginning in 2003, Mr. Grant has served as Director, Chairman of the Board, CEO, President, COO, and CFO of Biolase Technology. From 1997-2003, he held various senior management positions at Lumenis.
Mr. Grant holds a BA from Brigham Young University and an MBA with Honors from Thunderbird School of Global Management. He has also attended the President's Seminar at Harvard Business School. He has lived and worked in nine countries and speaks Japanese, French, Korean, and German fluently.
Vice President & US Head, Aesthetics and OTC, Merz North America
Jim currently serves as Vice President & US Head, Aesthetics and OTC for Merz North America. In this role, he leads the commercial efforts for Aesthetics and OTC business units, with the goals of meeting and growing demand. He also directs and aligns U.S. Aesthetics / OTC operations with Merz’s global operations, ensuring all teams have the tools and support needed to achieve success.
Most recently, Jim served as Vice President, Global Marketing & Business Development for Obagi Medical Products, Inc. from 2009-2012. During his tenure at Obagi, Jim served as strategic marketing lead for domestic / international marketing and business development, successfully developing and launching 4 products and moving 4 into pre-launch phase.
From 2004 - 2009, Jim was Senior Vice President, US Commercial Operations for Stiefel Laboratories, Inc (now a division of Glaxo SmithKline) where he led commercial operations for the US Rx, Consumer and Aesthetic business units, including the acquisitions and integrations of Connetics (valued at $640 million) and Barrier Therapeutics, Inc. (valued at $148 million). Provided strategic direction for global R&D/portfolio planning and served as strategic partner for global marketing in the areas of aesthetics, acne and emerging therapies. During his tenure his team achieved top line growth of approximately 500% ($108M to $525M) and bottom line growth of 700% ($30M to $222M).
Prior to joining Stiefel, Jim served in several leadership roles in general management and sales within Allergan, SmithKline Beecham and Schering Plough. In 2004, he completed his tenure with Allergan as Director of Sales, Dermatology, where he successfully led the strategic execution of the launches of Botox® Cosmetic and Finacea™. Through his leadership, the division achieved its first annual performance of greater than $100 million (USD), resulting primarily from the accelerated growth of Tazorac®.
Jim completed his undergraduate studies at University of California, Irvine.
PhD, Vice President & General Manager, U.S. Aesthetic Aesthtics & Correctives Business Unit, Galderma Laboratories, L.P.
Kelly Huang, PhD, Vice President and General Manager, U.S. Aesthetic & Corrective Business Unit, is charged with leading all U.S. Aesthetic & Corrective Business activities,which includes a broad portfolio of treatments.
Kelly served Johnson & Johnson for 16 years, where he focused primarily on skincare, leading award‐winning product launches in cosmetic and OTC products as Vice President of R&D, Professional Sales & Marketing, and as Corporate Officer of J&J’s Neutrogena Corporation. More recently, he served as President of Endo Pharmaceuticals’ HealthTronics division, the urology device and services company, overseeing nearly a hundred physician partnerships delivering surgical services across the country, as well as for medical device R&D manufacturing, and sales & marketing.
Vice President, Sales and Marketing, Facial Aesthetics, Allergan. Inc.
David Moatazedi has been with Allergan for over 9 years and currently serves as Vice President of Sales and Marketing, Facial Aesthetics. In this position, David is responsible for the injectable portfolio which includes Botox® Cosmetic, JUVEDERM Family of Fillers, KYBELLA™.
David has an extensive background in Medical Aesthetics including Global Medical Marketing experience on Botox® Cosmetic, responsibility for introducing JUVEDERM® into the US market and achieving market leadership within 24 months, and most recently led the commercial integration of Kythera into the Facial organization. Prior to his current role, David was Vice President, Sales and Marketing for U.S. Plastic Surgery with a focus on development of the Natrelle® 410 shaped implant and commercialization of the highly innovative SERI® Surgical Scaffold.
Prior to joining Allergan, David held various positions at Novartis Pharmaceuticals as District Sales Manager, Market Research Manager, and Sales Representative. He holds an MBA in Marketing from Pepperdine University and a B.A. Degree in chemistry from California State University, Long Beach.
Previous Award Recipients
Lifetime of Contributions to Dermatology Award
Innovator in Dermatology
Leaders of Industry Award
2012Richard E. Fitzpatrick, M.D., F.A.A.D., Founder of SkinMedica
Diane Ranger, Founder of Colorscience, Inventor of Powder Sunscreen